New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

41

Cortexyme Charts New Course with Acquisition of Rare Disease Player

Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.

42

Pfizer to pay $11.6 billion for Biohaven to tap migraine market

Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.

43

Pharmacy chains should pay $878 million for opioid epidemic role, Ohio counties say

A lawyer for two Ohio counties said CVS Health Corp., Walgreens Boots Alliance Inc. and Walmart Inc. should fund an $878 million plan to address the opioid crisis there, as a first-of-its-kind trial got underway to determine the pharmacy chains’ contribution.

45

CrowdPharm Named to Inc. Magazine’s 2022 Best Workplaces

CrowdPharm, a full-service agency with the largest network of global talent in healthcare, was named to Inc. Magazine’s annual Best Workplaces list. The list results from a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture, whether operating in a physical or virtual facility.

46

CMI Media Group and Compas Announce Increased Investment in Staff Learning and Development Led by Employee Feedback

Underscoring an investment in the growth, development and engagement of their talent, WPP company CMI Media Group and NMSDC certified diverse supplier Compas announced the launch of University Learning Services, a dedicated team that will benefit the agency’s ability to scale and create even more dynamic career pathing.

49

Eisai, Biogen take another step toward potential approval of Alzheimer’s drug

Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.